Figure 2
From: Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
Two-dimensional histogram of the KRAS 5-plex assay for detection of KRAS mutations in plasma and relationship between detectability of mutant KRAS in plasma cell-free DNA (cfDNA) and UICC-stage.
(A) Controls. Fragmented KRAS mutant and non-mutant genomic DNA reference standards were used. Representative views of droplet digital PCR plots using plasma cell-free DNA show no mutant KRAS alleles (B), G12V-mutant KRAS alleles (C) and G12D-mutant KRAS alleles (D). The x-axis and the y-axis correspond respectively to the FAM and VIC intensity (arbitrary units). (E) The number of patients with or without detectable levels of KRAS mutations in plasma in UICC-stages IA to IV. (F) The fraction of mutant KRAS in plasma cfDNA in UICC-stages IA to IV.
